Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO 140 in HIV-Infected Injection Drug Users
NCT01272258Phase 2Withdrawn
- Sponsor
- CytoDyn Inc.
- Start
- Dec 2013
- Primary completion
- Jan 2017
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of leronlimab in human immunodeficiency virus infection (HIV), sponsored by CytoDyn Inc.. Planned start Dec 2013; status: withdrawn.
02
Drugs
leronlimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01272258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01272258.